Takeda Pharmaceutical Company Limited

Symbol: TKPHF

PNK

26.83

USD

Market price today

  • 36.7423

    P/E Ratio

  • 0.0061

    PEG Ratio

  • 42.09B

    MRK Cap

  • 0.00%

    DIV Yield

Takeda Pharmaceutical Company Limited (TKPHF) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.68%

Operating Profit Margin

0.08%

Net Profit Margin

0.04%

Return on Assets

0.01%

Return on Equity

0.03%

Return on Capital Employed

0.03%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Christophe Weber
Full-time employees:49095
City:Tokyo
Address:1-1, Nihonbashi-Honcho 2-chome
IPO:2008-06-25
CIK:0001395064

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

General Outlook

When we look at how much money they make before expenses, they keep 0.675% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.075%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.043%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.013% return, is a testament to Takeda Pharmaceutical Company Limited's adeptness in optimizing resource deployment. Takeda Pharmaceutical Company Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.026%. Furthermore, the proficiency of Takeda Pharmaceutical Company Limited in capital utilization is underscored by a remarkable 0.026% return on capital employed.

Stock Prices

Takeda Pharmaceutical Company Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $27.1, while its low point bottomed out at $26.62. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Takeda Pharmaceutical Company Limited's stock market.

Liquidity Ratios

Analyzing TKPHF liquidity ratios reveals its financial health of the firm. The current ratio of 106.43% gauges short-term asset coverage for liabilities. The quick ratio (46.47%) assesses immediate liquidity, while the cash ratio (12.64%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio106.43%
Quick Ratio46.47%
Cash Ratio12.64%

Profitability Ratios

TKPHF profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 3.56% underscores its earnings before tax deductions. The effective tax rate stands at -20.31%, revealing its tax efficiency. The net income per EBT, 120.23%, and the EBT per EBIT, 47.40%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 7.50%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin3.56%
Effective Tax Rate-20.31%
Net Income per EBT120.23%
EBT per EBIT47.40%
EBIT per Revenue7.50%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.06, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding46
Days of Inventory Outstanding315
Operating Cycle380.37
Days of Payables Outstanding130
Cash Conversion Cycle250
Receivables Turnover5.61
Payables Turnover2.80
Inventory Turnover1.16
Fixed Asset Turnover2.26
Asset Turnover0.29

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 466.22, and free cash flow per share, -82.25, depict cash generation on a per-share basis. The cash per share value, 202.31, showcases liquidity position. A payout ratio of 1.62 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.18, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share466.22
Free Cash Flow per Share-82.25
Cash per Share202.31
Payout Ratio1.62
Operating Cash Flow Sales Ratio0.18
Free Cash Flow to Operating Cash Flow Ratio-0.18
Cash Flow Coverage Ratio0.16
Short Term Coverage Ratio1.98
Capital Expenditure Coverage Ratio0.85
Dividend Paid and Capex Coverage Ratio0.64
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 32.79%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.69, we discern the balance between debt and equity financing. The long-term debt to capitalization, 38.91%, and total debt to capitalization, 40.89%, ratios shed light on its capital structure. An interest coverage of 1.45 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio32.79%
Debt Equity Ratio0.69
Long Term Debt to Capitalization38.91%
Total Debt to Capitalization40.89%
Interest Coverage1.45
Cash Flow to Debt Ratio0.16
Company Equity Multiplier2.11

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2595.34, provides a glimpse into top-line earnings distributed across each share. Net income per share, 204.29, reflects the portion of profit attributed to each share. The book value per share, 4094.65, represents the net asset value distributed per share, while the tangible book value per share, -1743.58, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2595.34
Net Income Per Share204.29
Book Value Per Share4094.65
Tangible Book Value Per Share-1743.58
Shareholders Equity Per Share4094.65
Interest Debt Per Share2933.38
Capex Per Share-408.36

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 12.85%, indicates top-line expansion, while the gross profit growth, 13.05%, reveals profitability trends. EBIT growth, 6.44%, and operating income growth, 6.44%, offer insights into operational profitability progression. The net income growth, 37.80%, showcases bottom-line expansion, and the EPS growth, 38.84%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth12.85%
Gross Profit Growth13.05%
EBIT Growth6.44%
Operating Income Growth6.44%
Net Income Growth37.80%
EPS Growth38.84%
EPS Diluted Growth38.44%
Weighted Average Shares Growth-0.75%
Weighted Average Shares Diluted Growth-0.46%
Dividends per Share Growth-0.76%
Operating Cash Flow Growth-13.00%
Free Cash Flow Growth-63.35%
10-Year Revenue Growth per Share31.57%
5-Year Revenue Growth per Share14.46%
3-Year Revenue Growth per Share22.80%
10-Year Operating CF Growth per Share61.55%
5-Year Operating CF Growth per Share30.12%
3-Year Operating CF Growth per Share46.41%
10-Year Net Income Growth per Share22.88%
5-Year Net Income Growth per Share-14.65%
3-Year Net Income Growth per Share619.06%
10-Year Shareholders Equity Growth per Share49.66%
5-Year Shareholders Equity Growth per Share60.06%
3-Year Shareholders Equity Growth per Share34.99%
10-Year Dividend per Share Growth per Share0.02%
5-Year Dividend per Share Growth per Share-0.92%
3-Year Dividend per Share Growth per Share-0.78%
Receivables Growth-5.89%
Inventory Growth15.62%
Asset Growth5.92%
Book Value per Share Growth12.65%
Debt Growth0.85%
R&D Expense Growth20.38%
SGA Expenses Growth12.52%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 10,616,251,400,563.566, captures the company's total value, considering both debt and equity. Income quality, 3.08, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 64.91%, indicates the value of non-physical assets, and capex to operating cash flow, -64.85%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value10,616,251,400,563.566
Income Quality3.08
Research and Development to Revenue15.73%
Intangibles to Total Assets64.91%
Capex to Operating Cash Flow-64.85%
Capex to Revenue-15.73%
Capex to Depreciation-95.38%
Stock-Based Compensation to Revenue1.51%
Graham Number4338.32
Return on Tangible Assets6.47%
Graham Net Net-3895.37
Working Capital-83,984,000,000
Tangible Asset Value-2,705,709,000,000
Net Current Asset Value-5,205,123,000,000
Invested Capital1
Average Receivables703,035,000,000
Average Payables582,765,000,000
Average Inventory919,812,000,000
Days Sales Outstanding62
Days Payables Outstanding190
Days of Inventory On Hand289
ROIC3.86%
ROE0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.97, and the price to book ratio, 0.97, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.57, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -50.75, and price to operating cash flows, 8.95, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.97
Price to Book Ratio0.97
Price to Sales Ratio1.57
Price Cash Flow Ratio8.95
Price Earnings to Growth Ratio0.01
Enterprise Value Multiple1.93
Price Fair Value0.97
Price to Operating Cash Flow Ratio8.95
Price to Free Cash Flows Ratio-50.75
Price to Tangible Book Ratio1.07
Enterprise Value to Sales2.64
Enterprise Value Over EBITDA8.78
EV to Operating Cash Flow10.86
Earnings Yield4.68%
Free Cash Flow Yield5.08%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Takeda Pharmaceutical Company Limited (TKPHF) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 36.742 in 2024.

What is the ticker symbol of Takeda Pharmaceutical Company Limited stock?

The ticker symbol of Takeda Pharmaceutical Company Limited stock is TKPHF.

What is company IPO date?

IPO date of Takeda Pharmaceutical Company Limited is 2008-06-25.

What is company current share price?

Current share price is 26.830 USD.

What is stock market cap today?

The market cap of stock today is 42094485859.000.

What is PEG ratio in 2024?

The current 0.006 is 0.006 in 2024.

What is the number of employees in 2024?

In 2024 the company has 49095.